Back to Directory

Coleen Cunningham

Email

CKCunnin@UCI.edu

Phone

714-456-8470

Institution

University of California, Irving

Address

University of California, Irvine
3800 W. Chapman Ave
Suite 2200
Orange, CA 92868
USA

Request an Update

Affiliated Studies

IMPAACT 2048: Phase I Study of the Safety and Pharmacokinetics of VRC07-523LS, ePGT121v1-LS, and PDGM1400LS Alone and in Combination in Breastfeeding Infants

Research Area

Study Status

IMPAACT 2038: Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vector Vaccines B/HPIV3/RSV/PreF, B/HPIV3/RSV/PreF/TM, or Placebo, Delivered via Nasal Sprayer to HPIV3-Seronegative Children 6 to 24 Months of Age

DAIDS Number

Research Area

Cure and Immunotherapy

Study Status

IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1

DAIDS Number

Research Area

Study Status

P1096: Phase 1 Study of Live Attenuated Recombinant (cp) 45 Human Parainfluenza Type 3 Vaccine

DAIDS Number

Research Area

Study Status

IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

DAIDS Number

Research Area

Cure and Immunotherapy

Study Status

Participants Off Study and Primary Analysis Completed

Show All